BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 21, 2013--
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, today announced
the expansion of its senior management team with the appointment of
Lesley Stolz, Ph.D. as Executive Vice President, Corporate Development.
Dr. Stolz has more than 18 years of life science industry experience in
corporate and business development.
“Lesley brings a strong background in corporate and business development
to BioTime including more than twenty successfully concluded technology
and therapeutics partnering and financing transactions in the life
sciences,” said Michael D. West, PhD, BioTime’s Chief Executive Officer.
“She will have primary responsibility for interactions with both
investors and corporate partners. Additionally, she will focus on
identifying and implementing strategic initiatives for BioTime and its
subsidiaries. As we complete the building of our leading technology and
intellectual property position in regenerative medicine and begin
clinical trials with multiple products, Lesley will work with corporate
partners and investors on the next stage of BioTime’s development. As
with previous new technologies in the history of biotechnology, it is
likely that many regenerative medicine therapeutics will be developed
through partnerships between biotechnology companies and commercial
Prior to joining BioTime, Dr. Stolz was vice president of business
development for Sutro Biopharma, Inc., a company focused on protein
therapeutics, where she was responsible for all corporate partnering
activities as well as business strategy development and implementation,
and capital raising. Earlier in her career, Dr. Stolz worked with
Sunesis Pharmaceuticals,Inc., Aerovance, Inc., and GPC Biotech AG in
Munich, Germany. Dr. Stolz holds a Ph.D. in chemistry from the
University of Rochester, and a bachelor of science degree in chemistry
from the University of Virginia. She conducted postdoctoral research at
the Harvard Medical School Department of Biochemistry and Molecular
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary PureStem™
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood
plasma volume expander for use in surgery, emergency trauma treatment
and other applications. Hextend® is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
ES Cell International Pte Ltd., a Singapore private limited company,
develops hES products for research use.
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of blood and lymphatic vascular disorders, as well as products for
research using iPS and other cell reprogramming technology.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company
focused on developing stem cell-based therapies for retinal and
neurological degenerative diseases. Its lead product is OpRegen®
for the treatment of macular degeneration.
LifeMap Sciences, Inc. markets, sells and distributes GeneCards®,
the leading human gene database, the leading human gene database, as
part of an integrated database suite that also includes the LifeMap
Discovery™ database of embryonic development, stem cell research
and regenerative medicine, and MalaCards, the human disease
database. LifeMap Sciences also markets BioTime research products and PanDaTox,
an innovative, recently developed, searchable database that can aid in
the discovery of new antibiotics and biotechnologically beneficial
Asterias Biotherapeutics, Inc. is a new subsidiary being used to
acquire the stem cell assets of Geron Corporation, including patents
and other intellectual property, biological materials, reagents and
equipment for the development of new therapeutic products for
Additional information about BioTime can be found on the web at www.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com
Source: BioTime, Inc.
Robert Peabody, 510-521-3390 ext. 302
Sr. VP &
Segall, 510-521-3390 ext. 301